Journal News

Stem cells: Nefarious escape artists of a rare disease

Sarah May
July 5, 2022

There is no cure for Niemann–Pick type C1, or NPC1, disease — a progressive neurological condition that often begins in infancy. With early onset, children may live for only five years. One of the first signs of NPC1 disease is a swollen abdomen due to an enlarged liver or spleen. Doctors and researchers do not yet know what causes this, but left untreated, it can be life-threatening.

A colorized image of a human stem cell (yellow) embedded within a 3D matrix that mimics the bone marrow environment, as captured by cryo-scanning electron microscopy.
Sílvia A Ferreira, Cristina Lopo and Eileen Gentleman, KCL.
A colorized image of a human stem cell (yellow) embedded within a 3D matrix
that mimics the bone marrow environment, as captured by cryo-scanning
electron microscopy.

NPC1 disease is caused by mutations in the NPC1 gene, which encodes a protein that transports cholesterol. In a 2008 study, researchers suggested that hepatic loss of NPC1 induced extramedullary hematopoiesis (the generation of white blood cells from stem cells outside the bone marrow) in the liver. There, the stem cells proliferate and contribute to an enlarged and inflamed liver. However, they found no direct proof of extramedullary hematopoiesis, and effects on the spleen were unclear.

In a recent study published in the Journal of Lipid Research, Anouk Groenen, Anouk La Rose and colleagues at the University Medical Center Groningen report that loss of NPC1 in hematopoietic stem cells triggered stem cells to leave the bone marrow and invade the spleen.

It was NPC1’s role in cholesterol trafficking, a research focus of their laboratory, that first caught the researchers’ attention. NPC1’s normal function, which shuts down in NPC1 disease, is to empty out cholesterol from storage compartments inside the cell.

When the team deleted NPC1 from hematopoietic stem cells in mice with high cholesterol, something was obviously happening. They noticed that the bones of these mice were almost white, La Rose said. “We saw that there were almost no stem cells left in the bone marrow and that they had migrated to the spleen, and we were very surprised to see this.”

Hematopoietic stem cells leave the bone marrow in response to a growth factor called granulocyte-colony stimulating factor. If growth factor levels are kept in check, the stem cells stay in the bone marrow where they belong. In the research team’s mouse model, growth factor expression went up. It was also higher in NPC1 patients than people without the disease.

“I think this is a first step — to look at the things that we see in the mice, if this also happens in NPC1 patients,” Groenen said.

Next, they would like to see that the hematopoietic stem cells are entering the blood in NPC1 patients, La Rose said. “If we can show that, then it’s very likely that, indeed, they also go to the spleen and perhaps the liver in the patients.”

One potential link between loss of NPC1, elevated growth factor and stem cell mobilization is buildup of 7-ketocholesterol. This oxidized form of cholesterol is a main component of oxidized low-density lipoprotein, one of the major cholesterol carriers in the blood.

Previously, a small clinical trial attempted to raise levels of E06 antibodies that neutralize oxidized low-density lipoprotein. It was unsuccessful in raising E06 levels, Groenen explained, and there were no NPC1 patients in the study.

“I think for future studies it will be very interesting to find a way to raise E06 levels in patients,” La Rose said. If successful, this might halt the progression of NPC1 disease.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Sarah May

Sarah May is a scientific writer at the University of Chicago.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Melissa Moore to speak at ASBMB 2025
ASBMB Annual Meeting

Melissa Moore to speak at ASBMB 2025

April 2, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.

 A new kind of stem cell is revolutionizing regenerative medicine
Feature

A new kind of stem cell is revolutionizing regenerative medicine

April 1, 2025

Induced pluripotent stem cells are paving the way for personalized treatments to diabetes, vision loss and more. However, scientists still face hurdles such as strict regulations, scalability, cell longevity and immune rejection.

Engineering the future with synthetic biology
ASBMB Annual Meeting

Engineering the future with synthetic biology

March 31, 2025

Learn about the ASBMB 2025 symposium on synthetic biology, featuring applications to better human and environmental health.

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance
Webinar

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance

March 28, 2025

Alejandro Vila, an ASBMB Breakthroughs speaker, discussed his work on metallo-β-lactamase enzymes and their dependence on zinc.

Host vs. pathogen and the molecular arms race
ASBMB Annual Meeting

Host vs. pathogen and the molecular arms race

March 28, 2025

Learn about the ASBMB 2025 symposium on host–pathogen interactions, to be held Sunday, April 13 at 1:50 p.m.

Richard Silverman to speak at ASBMB 2025
ASBMB Annual Meeting

Richard Silverman to speak at ASBMB 2025

March 27, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.